Clinical profiles of celecoxib and rofecoxib in the rheumatic diseases

Journal of Hypertension

Volumn 20, Issue SUPPL. 6, 2002, Pages

  Gibofsky, Allan ^a,b  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b HOSPITAL FOR SPECIAL SURGERY   (United States)

Author keywords

Cyclooxygenase; Non steroidal anti inflammatory drugs; Osteoarthritis; Rheumatoid arthritis

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; ETODOLAC; FLURBIPROFEN; IBUPROFEN; INDOMETACIN; MECLOFENAMIC ACID; NABUMETONE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PHENYLBUTAZONE; PIROXICAM; ROFECOXIB; SULINDAC;

CLINICAL FEATURE; CLINICAL TRIAL; CONFERENCE PAPER; DRUG APPROVAL; DRUG EFFICACY; DRUG MECHANISM; DRUG SPECIFICITY; ENZYME INHIBITION; ENZYME SPECIFICITY; GASTROINTESTINAL MUCOSA; GASTROINTESTINAL TOXICITY; HUMAN; IC 50; OSTEOARTHRITIS; PRIORITY JOURNAL; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; STOMACH DISEASE;

EID: 0036763816     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004872-200212000-00001     Document Type: Conference Paper

References (31)

1. IMS America, Norwalk, CT, USA, 1998.
2. Wolfe MM, Lichtenstein DR, Singh G. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med 1999; 340:1888-1899.
3. Singh G, Triadafilopoulos G. Epidemiology of NSAID-induced GI complications. J Rheumatol 1999; 26 (suppl 26):18-24.
4. Singh G. Recent considerations in nonsteroidal anti-inflammatory drug gastropathy. Am J Med 1998; 205:31S-38S.
5. Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nature 1971; 231:232-235.
6. Vane JR, Flower RJ, Botting RM. History of aspirin and its mechanism of action. Stroke 1990; 21 (suppl IV):IV-12-1V-23.
7. Collier HOJ. A pharmacologic analysis of aspirin. Adv Pharmacol Chemother 1969; 7:333-405.
8. Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for the aspirin-like drugs. Nature 1971; 231:232-235.
9. Vane JR, Botting RM. New insights into the mode of action of anti-inflammatory drugs. Inflamm Res 1995; 44:1-10.
10. Patrignani P, Panara MR, Greco A, Fusco O, Natoli C, lacobelli S, et al. Biochemical and pharmacological characterization of the cyclooxygenase activity of human blood prostaglandin endoperoxide synthases. J Pharmacol Exp Ther 1994; 271:1705-1712.
11. Vane JR. Mechanism of action of NSAIDs. Br J Rheumatol 1996; 35(suppl 1):1-3.
12. Fu JU, Masferrer JL, Seibert K, Raz A, Needleman P. The induction and suppression of prostaglandin H2 synthase (cyclooxygenase) in human monocytes. J Biol Chem 1990; 265:12866-12872.
13. 2-dependent plaque instability. Circulation 2001; 104:921-927.
14. Smith WL, DeWitt DL. Biochemistry of prostaglandin endoperoxide H synthase-1 and synthase-2 and their differential susceptibility to NSAIDs. Semin Nephrol 1995; 15:179-194.
15. Meade EA, Smith WL, DeWitt DL. Differential inhibition of prostaglandin endoperoxide synthase (cyclooxygenases) isozymes by aspirin and the other non-steroidal anti-inflammatory drugs. J Biol Chem 1993; 268:6610-6614.
16. Laneuville O, Breuer DK, DeWitt DL, Hla T, Funk CD, Smith WL. Differential inhibition of human prostaglandin endoperoxide H synthases-1 and -2 by non-steroidal anti-inflammatory drugs. J Pharmacol Exp Ther 1994; 271:927-934.
17. Spangler RS. Cyclooxygenase 1 and 2 in rheumatic disease: Implications for NSAID therapy. Semin Arthritis Rheum 1996; 26:435-446.
18. Celecoxib Package Insert, Pharmacia Corp., 2001.
19. Vioxx Package Insert, Merck & Co., Inc., 2001.
20. Goldstein JL, Correa P, Zhao WW, Burr AM, Hubbard RC, Verburg KM, Geis GS. Reduced incidence of gastroduodenal ulcers with celecoxib, a novel cyclooxygenase-2 inhibitor, compared to naproxen in patients with arthritis. Am J Gastroenterol 2001; 96:1019-1027.
21. Cannon GW, Caldwell JR, Holt P, McLean B, Seidenberg B, Bolognese J, et al. Rofecoxib, a specific inhibitor of cyclooxygenase 2, with clinical efficacy comparable with that of diclofenac sodium. Arthritis Rheum 2000; 160:1781-1787.
22. McKenna F, Weaver A, Fiechtner JJ, Bello AE, Fort JG. COX-2 specific inhibitors in the management of osteoarthritis of the knee. A placebo-controlled, randomized, double-blind study. J Clin Rheumatol 2001; 7:151-159.
23. Geis GS. Update on clinical developments with celecoxib, a new specific COX-2 inhibitor: What can we expect? J Rheumatol 1999; 26 (suppl 56):31-36.
24. Armstrong CP, Blower AL. Non-steroidal anti-inflammatory drugs and life-threatening complications of peptic ulceration. Gut 1987; 28:527-532.
25. Singh G, Ramey DR, Morfeld D, Shi H, Hatoum HT, Fries JF. Gastrointestinal tract complications of nonsteroidal anti-inflammatory drug treatment in rheumatoid arthritis. A prospective observational cohort study. Arch Intern Med 1996; 156:1530-1536.
26. Simon LS, Weaver AL, Graham DY, Kivitz AJ, Lipsky PE, Hubbard RC, et al. Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: A randomized controlled trial. JAMA 1999; 282:1921-1928.
27. Laine L, Harper S, Simon T, Bath R, Johanson J, Schwartz H, et al. A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2-specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis. Gastroenterology 1999; 117:776-783.
28. Hawkey C, Laine L, Simon T, Beaulieu A, Maldonado-Cocco J, Acevedo E, et al. Comparison of the effect of rofecoxib (a cyclooxygenase 2 inhibitor), ibuprofen, and placebo on the gastroduodenal mucosa of patients with osteoarthritis: A randomized, double-blind, placebo-controlled trial. The Rofecoxib Osteoarthritis Endoscopy Multinational Study Group. Arthritis Rheum 2000; 43:370-377.
29. Emery P, Zeidler H, Kvien KT, Guslandi M, Nauden R, Stead H, et al. Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: Randomised double-blind comparison. Lancet 1999; 354:2106-2111.
30. Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis. The CLASS study: A randomized controlled trial. J Am Med Assoc 2000; 284:1247-1255.
31. Bombardier C, Laine L, Reicin A, Shapiro D, Brugos-Vargas R, Davis B, et al. Comparison of the upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 2000; 343:1520-1528.